EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Triage performance of DNA methylation for women with high-risk human papillomavirus infection

Linghua Kong, Xiaoping Xiao, Huanwen Wu, Yan You, Xitong Jin, Yuligh Liou, Pei Liu, Jinghe Lang, Lei Li iD

The Oncologist · 2025

DOI: 10.1093/oncolo/oyae324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Linghua Kong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing 100730, People's Republic of China. Hauptthemen laut MEDLINE: DNA Methylation, Papillomavirus Infections, Uterine Cervical Neoplasms, Uterine Cervical Dysplasia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

DNA methylation is a promising biomarker for cervical cancer screening. This study aimed to validate the triage performance of cytological DNA methylation for detecting cervical intraepithelial neoplasia of grade 3 or worse (CIN3+) in women with high-risk human papillomavirus (hrHPV) infection from a large prospective cohort undergoing opportunistic screening in China (METHY3).

Methods

The triage performance for detecting CIN3+ lesions was compared between HPV16/18 genotyping, a liquid-based cytology (LBC) test, and the PAX1 and JAM3 methylation (PAX1m/JAM3m) test according to cervical pathologic outcomes. Among the 4394 women infected with hrHPV, 1105 had definitive cervical histological findings that were analyzed.

Results

For detecting CIN3+, the specificity of HPV16/18(+), the LBC result of ≥atypical squamous cells of undetermined significance (ASCUS), and PAX1m/JAM3m(+) was 66.4%, 23.9%, and 89.6%, respectively, with odds ratios of 4.24 (95% confidence interval [CI], 2.85-6.40), 4.44 (2.27-10.1), and 18.5 (12.1-28.7) (P < .001), respectively. PAX1m/JAM3m(+) had the highest area under the receiver operating characteristic curve (0.790, 95% CI, 0.747-0.832) in the whole cohort and in women of various ages. PAX1m/JAM3m (+) was detected in all patients with cancer (n = 28). Compared with HPV16/18 genotyping and the LBC test, PAX1m/JAM3m testing reduced referrals to colposcopy by 20.64 percentage points and 61.18 percentage points, respectively.

Conclusions

PAX1 m /JAM3 m testing is highly specific for detecting CIN3+. As a triage biomarker, it is superior to HPV 16/18 genotyping and LBC testing for women with hrHPV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationPapillomavirus InfectionsUterine Cervical NeoplasmsUterine Cervical DysplasiaHumansFemaleMiddle AgedAdultTriageHuman papillomavirus 16Human papillomavirus 18Early Detection of CancerProspective StudiesPaired Box Transcription FactorsAgedChinaCell Adhesion Molecules

Stichwörter der Autor:innen

CIN3DNA methylationHPV genotypecervical screeningcytology test

Substanzen

PAX1 transcription factorPaired Box Transcription FactorsCell Adhesion Molecules

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing 100730, People's Republic of China.
  • National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing 100730, People's Republic of China.
  • State Key Laboratory for Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing 100730, People's Republic of China.
  • Department of Pathology, Peking Union Medical College Hospital, Beijing 100730, People's Republic of China.
  • Department of Medical Laboratory, Beijing Origin-Poly Bio-Tec Co., Ltd., Beijing 102600, People's Republic of China.
  • Clinical Precision Medicine Research Center, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510062, People's Republic of China.

ORCID-Profile: Lei Li

Zitieren

APA

Kong, L., Xiao, X., Wu, H., You, Y., Jin, X., Liou, Y., Liu, P., Lang, J., & Li, L. (2025). Triage performance of DNA methylation for women with high-risk human papillomavirus infection. The Oncologist. https://doi.org/10.1093/oncolo/oyae324

Vancouver

Kong L, Xiao X, Wu H, You Y, Jin X, Liou Y, et al. Triage performance of DNA methylation for women with high-risk human papillomavirus infection. The Oncologist. 2025. doi:10.1093/oncolo/oyae324

BibTeX
@article{Kong2025,
  author = {Kong, Linghua and Xiao, Xiaoping and Wu, Huanwen and You, Yan and Jin, Xitong and Liou, Yuligh and Liu, Pei and Lang, Jinghe and Li, Lei},
  title = {Triage performance of DNA methylation for women with high-risk human papillomavirus infection},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyae324}
}
Kostenlos starten →